U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. **FORM PTO-1449** 10/086,217 PATENT AND TRADEMAR A061CIP2 CONFIRMATION NO. APPLICANT INFORMATION DISCLOSURF Gregory R. Mundy and 5114 STATEMENT BY APPLICANTO Toshiyuki Yoneda FILING DATE **GROUP** JUL 1 1 2002 February 21, 2002 1644 **U.S. PATENT DOCUMENTS EXAMINER SUBCLASS** DATE NAME **CLASS** DOCUMENT NUMBER INITIAL APPROPRIATE W+ 5,510,332 4/23/96 Kogan et al. 514 14 July 7, 1994 FOREIGN PATENT DOCUMENTS TRANSLATION **EXAMINER** COUNTRY **CLASS SUBCLASS** DOCUMENT NUMBER DATE INITIAL YES NO WO 99/61421 12/2/99 **PCT** C07D 207/10 → MH WO 00/15247 3/23/00 **PCT** A61K 38/17 mu **PCT** WO 01/12186 2/22/01 A61K 31/40 wat-

EXAMINER

Maker Haddad

DATE CONSIDERED

10/27/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1	PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
INFORMATION DISCLOSURE STATEMENT BY APPLICAN O		APPLICANT Gregory R. Mundy and Toshiyuki Yoneda FILING DATE	CONFIRMATION NO. 5114 GROUP RECEIVED
	AITEM S. THAIR	February 21, 2002	GROUP RECEIVED
	OTHER DOCUMENTS (Including Author, Title	e, Date, Pertinent Pages, Etc	E.) TECH
EXAMINER INITIAL			TECH CENTER 1600/2900
MH	Masellis-Smith et al. "Adhesion of Multiple Myeloma Requirement for CD44 and $\alpha_4\beta_7$ ", Cancer Research		Marrow Fibroblasts: A
m H	Roodman GD "Mechanisms of Bone Lesions in Mult 'Online!: US National Library of Medicine (NLM), Bet accession no. 1998026745, abstract.		
m++	Roodman GD "Mechanisms of Bone Lesions in Mult Suppl): 1557-1563 (1997, Oct. 15).	iple Myeloma and Lymphom	a", <u>Cancer</u> 80 (8
mH	Akatsu et al. "Chinese Hamster Ovary Cells Expressi Formation In Vitro", <u>Database BIOSIS 'Online!</u> : <u>Bios</u> (August 1998) Database accession no. PREV19980	ciences Information Service	
m4	Akatsu et al."Chinese Hamster Ovary Cells Expressi Vitro", Journal of Bone and Mineral Research 13 (8		steoclast Formation In
mtt	Michigami et al. "Interactions of Myeloma Cells with Integrin - VCAM-1 is required for the Development or retrieved from STN, Database accession no. 684996	f Osteolysis", <u>Database SCI</u>	
THE	Michigami et al. "Interactions of Myeloma Cells with I VCAM-1 is required for the Development of Osteolys Supp. 1, p.S 128, Abstract 104 (1997).	Bone Marrow Stromet Colls is , Journal of Bone and Mir	via α _ε β _τ Integrio - neral Research 12
мн	Mori et al. "Anti- α 4 Integrin Antibody Suppresses the Myeloma-marrow Stromal Cell Interactions", <u>Journal</u> S173, Abstract 1161 (1999).		
			
	: 		
			
	· · · · · · · · · · · · · · · · · · ·		

EXAMINER maker the solard

DATE CONSIDERED

40/22/01

OCT 2 0 2003 E

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 10274-063001

Application No. 10/086,217

Information Disclosur Statement by Applicant

(Use several sheets if necessary)

Applicant Mundy et al.

Filing Date

Group Art Unit 1644

(37 CFR §1.98(b))

February 21, 2002

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA		<u> </u>				
	AB					1	
	AC						,
	AD						
	AE						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AF							
	AG							
	AH							

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.					
Initial	ID	Document				
MH	ΑI	Damiano et al., "Integrin-Mediated Drug Resistance in Multiple Myeloma", 2000, Leukemia and Lymphama, vol. 38 (1-2):71-81				
MH	AJ	Damiano et al., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins", March 1, 1999, Blood, vol. 93(5):1658-1667				
m#	AK	Mundry et al., "Stromal cells regulate survival of B-lineage leukemic cells", Sept. 1, 2000, Blood, vol. 96 (5):1926-1932				

Examiner Signature	Date Considered
Maker Haddad	10/23/04
EXAMINER: Initials citation considered. Draw line through citation if no	of in conformance and not considered. Include copy of this form with
next communication to applicant.	*

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE O STATEMENT BY APPLICANT JUN 2 1 2002

ATTY. DOCKET NO.	SERIAL NO.
A061CIP2	10/086,217
APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
FILING DATE	GROUP
February 21, 2002	1644

U.S. PATENT DOCUMENTS

		U.S. PATI	ENT DOCUME	:N12		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
mt	US 2002/0022028 A1	2/21/2002	Mundy et al.	424	142.1	March 13, 2001
mH	US 2002/0041874 A1	4/11/2002	Mundy et al.	424	131.1	August 31, 2001
		·				

EXAMINER	Mahon	Hoddad
	,	

DATE CONSIDERED

10/27/04

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
	FORMATION DISCLOSURE CONTACT ATEMENT BY APPLICANT	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	STATEMENT BY APPLICANT JUN 2 1 2002	FILING DATE February 21, 2002	GROUP 1644
	OTHER DOCUMENTS (Including Author, T	itle, Date, Pertinent Pages, E	itc.)
EXAMINER INITIAL			

EXAMINER INITIAL	
mas	Alsina, M. et al., "Development of an In Vivo Model of Human Multiple Myeloma Bone Disease," <u>BLOOD</u> 87: 1495-1501 (1996).
man	Attal, M. et al., "A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma," N ENGL J MED 335: 91-97 (1996).
my	Atkins, C., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N. ENGL J MED 335: 1844 (1996).
mu	Oivanen, T. M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N ENG J MED 335: 1844-1845 (1996).
may	Attal, M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma - In Reply," N ENGL J MED 335: 1844-1845 (1996).
my	Barlogie, B. et al., "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients," <u>BLOOD</u> 98: 492-494 (2001).
my	Bataille, R. et al., "Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," J CLIN INVEST 84: 2008-2011 (1989).
my	Bataille, R. et al., "Mechanisms of Bone Lesions In Multiple Myeloma," <u>HEMATOLOGY/ONCOLOGY</u> CLINICS OF NORTH AMERICA 6: 285-295 (1992).
mu	Bataille, R. et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," <u>BLOOD</u> 86: 685-691 (1995).
hath-	Berenson, J. R. et al., "Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events," J CLIN ONCOL 16: 593-602 (1998).
ma	Seymour, J. F., "Correspondence: Long-Term Pamidronate in Multiple Myeloma," <u>J CLIN ONCOL</u> 16: 2572 (1998).
mts	Berenson, J. R., "Correspondence: Long-Term Pamidronate in Multiple Myeloma - In Reply," <u>J CLIN ONCOL</u> 16: 2572-2573 (1998).
hafe	Boyce, B. F. et al., "Bolus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice," ENDOCRINOLOGY 125: 2780-2783 (1989).
M. H.	Chauhan, D. et al., "Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells," STEM CELLS 13 (suppl 2): 35-39 (1995).
~ #	Dallas, S. L. et al., "Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease," BLOOD 93: 1697-1706 (1999).

EXAMINER

Maker Haddad

DATE CONSIDERED 10/27/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
INF ST	ORMATION DISCLOSURE O PE	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	JUN 2 1 2002 5	FILING DATE February 21, 2002	GROUP 1644
	T& TRADEMAN		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **EXAMINER** INITIAL Epstein, J., "Myeloma Phenotype; Clues To Disease Origin and Manifestation," HM HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA 6:249-256 (1992). mH Garrett, I. R. et al., "A Murine Model of Human Myeloma Bone Disease," BONE 20: 515-520 (1997). Gosslar, U. et al., "Predominant Role of α4-integrins for distinct steps of lymphoma metastasis," Proc. mH Natl. Acad. Sci. USA 93: 4821-4826 (1996). MacDonald, B. R. et al., "Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the m H Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures," J BONE AND MINERAL RESEARCH 1: 227-233 (1986). Matsuura, N. et al., "Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin α4β1 MH into Tumor Cells," AM J PATHOL 148: 55-61 (1996). Michigami, T. et al., "Interactions of Myeloma Cells with Bone Marrow Stromal Cells Via α4β1 Integrin-MH VCAM-1 Is Required For the Development of Osteolysis," Nineteenth Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio: Abstract 104 (9/14/1997); J. BONE AND MINERAL RESEARCH 12 Supplement: p. S218 (1997). Michigami, T. et al., "Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and MH α4β1-integrin enhances production of osteoclast-stimulating activity," BLOOD 96: 1953-1960 (2000). Mittelman, M. et al., "Erythropoietin induces tumor regression and antitumor immune responses in mH murine myeloma models," Proc. Natl. Acad. Sci. USA 98: 5181-5186 (2001) Mori, Y. et al., "Anti-α4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts MH Myeloma-Marrow Stromal Cell Interactions," Twenty-First Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, Missouri: Abstract 1161 (10/3/1999); J. BONE AND MINERAL RESERACH 14 Supplement 1: p. S148 (1999). Mundy, G. R. and Bertolini, D. R., "Bone Destruction and Hypercalcemia in Plasma Cell Myeloma," MH SEMINARS IN ONCOLOGY 13: 291-299 (1986). mH Mundy, G. R., "Myeloma Bone Disease," EURO J CANCER 34: 246-251 (1998). Oyajobi, B. O. et al., "Expression of Rank Ligand (RankL) By Myeloma Cells Requires Binding To Bone Marrow Stromal Cells Via An α4β1-VCAM-1 Interaction," Second Joint Meeting of The American MH Society for Bone and Mineral Research and The International Bone and Mineral Society, San Francisco, California: Abstract 1133 (12/4/1998); BONE 23(5 Supplement): p. S180 (1998). Papayannopoulou, T. and Nakamoto, B., "Peripheralization of hemopoietic progenitors in primates MH treated with anti-VLA, integrin," Proc. Natl. Acad. Sci. USA 90: 9374-9378 (1993). Qian, F. et al., "Expression of the Integrin α4β1 on Melanoma Cells Can Inhibit the Invasive Stage of MH Metastasis Formation," CELL 77: 335-347 (1994).

EXAMINER Maker Haddad DATE CONSIDERED 10/27/04

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
	ORMATION DISCLOSURE O PE	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	JUN 2 1 2002 3	FILING DATE February 21, 2002	GROUP 1644
	HADEN		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
EXAMINER INITIAL	
MH	Shimizu, N. et al., "Disruption of Cell-Cell Contact with Stromal Cells Using Anti-α4integrin Antibody Enhances Sensitivity of Myeloma Cells to Melphalan in Vitro and in Vivo," <u>Twenty-Third Annual Meeting of the American Society for Bone and Mineral Research, Phoenix, Arizona</u> : Presentation Number SU078 (10/14/2001).
мH	Tinhofer, I. et al., "Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma," <u>BLOOD</u> 95: 610-618 (2000).
mH	Vanderkerken, K. et al., "Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse," <u>BRIT J CANCER</u> 76: 451-460 (1997).

EXAMINER

Maker Haddad

DATE CONSIDERED 10/27/04